Phase II Trial of Capecitabine (Xeloda) and Weekly Docetaxel (Taxotere) in Metastatic Androgen Independent Prostate Carcinoma.

Trial Profile

Phase II Trial of Capecitabine (Xeloda) and Weekly Docetaxel (Taxotere) in Metastatic Androgen Independent Prostate Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2012

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2010 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
    • 20 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jun 2007 Interim results were presented at the 2007 American Society of Clinical Oncology (ASCO) meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top